Current Report Filing (8-k)
December 05 2016 - 5:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________________________
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 29, 2016
CROSSROADS CAPITAL, INC.
(Exact name of registrant as specified in
its charter)
Maryland
|
000-53504
|
26-2582882
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
128 N. 13th Street, #1100
Lincoln, Nebraska 68508
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code:
(402) 261-5345
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01 Entry Into Material Definitive Agreements.
On November 29, 2016, Crossroads Capital,
Inc. (the “Company”) sold 1,338,302 shares of Metabolon, Inc. Series D preferred stock for $3,466,202 to a purchaser
that is not affiliated with the Company, its officers, directors, or employees, nor any person
controlling or under common control with the Company or its affiliates
. The Company continues to own 890,719 shares of Metabolon
Series D preferred stock.
The Company and the purchaser of the Metabolon
stock each made customary representations and warranties to one another. Pursuant to the terms of the sale, and subject to certain
limitations, the parties to the Metabolon stock sale agreed to certain indemnification provisions with each other.
The Company issued a press release announcing
the disposition of its shares in Metabolon on December 5, 2016. A copy of the Company’s press release dated December 5, 2016,
is attached as Exhibit 99.1, and is incorporated herein by this reference.
Item 7.01 Regulation FD Disclosure.
The Company issued a press release announcing
the closing of its sales of Metabolon on December 5, 2016, a copy of which is attached as Exhibit 99.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated December 5, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 5, 2016
|
CROSSROADS CAPITAL, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Ben H. Harris, J.D.
|
|
|
Ben H. Harris, J.D.
|
|
|
President and Chief Executive Officer
|
Crossroads Capital, Inc. (NASDAQ:XRDC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Crossroads Capital, Inc. (NASDAQ:XRDC)
Historical Stock Chart
From Jul 2023 to Jul 2024